Pathology

Lubomir P. Turek, MD

Portrait

Staff Physician, Veterans Affairs Medical Center
Professor of Pathology

Contact Information

Primary Office: 10W11 Veterans Affairs Medical Center
Iowa City, IA 52242
Primary Office Phone: 319-338-0581

Email: lubomir-turek@uiowa.edu
Web: Dr. Turek's Research Laboratory

Education

MD, Charles University School of Medicine, Prague, Czech Republic

Student Research Assistant, Biology & Genetics, Czechoslovak Academy of Sciences, Institute Experimental Biology & Genetics, Prague, Czechoslovakia
Research Associate, Virology, Robert Koch Institute, West Berlin, Germany
Cancer Research Fellow of the Damon Runyon-Walter Winchell Fund, Tumor Virology, Department of Microbiology, University of Southern California, Los Angeles
Visiting Associate, Viral Carcinogenesis, National Cancer Institute, Bethesda, MD
Residency, Pathology, National Cancer Institute, Bethesda, MD

Licensure and Certifications

Educational Commission for Foreign Medical Graduates (ECFMG)

Education/Training Program Affiliations

Biosciences Graduate Program
Department of Pathology Graduate Program
Interdisciplinary Graduate Program in Molecular and Cellular Biology

Research Summary

Human papillomavirus transcriptional regulators in cell transformation and cancer.

Center, Program and Institute Affiliations

Holden Comprehensive Cancer Center

All Publications

Lace M, Ushikai M, Yamakawa Y, Anson J, Ishiji T, Turek L, Haugen T.  The truncated C-terminal E2 (E2-TR) protein of bovine papillomavirus (BPV) type-1 is a transactivator that modulates transcription in vivo and in vitro in a manner distinct from the E2-TA and E8^E2 gene products.  Virology.  2012 August. 429(2):99-111.
[PubMed]

Smith E, Rubenstein L, Haugen T, Pawlita M, Turek L.  Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease.  Journal of oncology.  2012. 2012:571862.
[PubMed]

Lace M, Anson J, Klussmann J, Wang D, Smith E, Haugen T, Turek L.  Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.  Journal of virology.  2011 February. 85(4):1645-54.
[PubMed]

Rubenstein L, Smith E, Pawlita M, Haugen T, Hamšíková E, Turek L.  Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study.  Infectious agents and cancer.  2011. 6:9.
[PubMed]

Smith E, Rubenstein L, Haugen T, Hamsikova E, Turek L.  Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers.  Cancer causes & control : CCC.  2010 September. 21(9):1369-78.
[PubMed]

Smith E, Pawlita M, Rubenstein L, Haugen T, Hamsikova E, Turek L.  Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.  International journal of cancer. Journal international du cancer.  2010 July. 127(1):111-7.
[PubMed]

Lace M, Anson J, Haugen T, Turek L.  Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes.  Virology.  2010 April. 399(2):270-9.
[PubMed]

Smith E, Parker M, Rubenstein L, Haugen T, Hamsikova E, Turek L.  Evidence for vertical transmission of HPV from mothers to infants.  Infectious diseases in obstetrics and gynecology.  2010. 2010:326369.
[PubMed]

Smith E, Rubenstein L, Hoffman H, Haugen T, Turek L.  Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer.  Infectious agents and cancer.  2010. 5:4.
[PubMed]

Lace M, Anson J, Klingelhutz A, Lee J, Bossler A, Haugen T, Turek L.  Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs.  Journal of virology.  2009 November. 83(22):11784-94.
[PubMed]

Lace M, Yamakawa Y, Ushikai M, Anson J, Haugen T, Turek L.  Cellular factor YY1 downregulates the human papillomavirus 16 E6/E7 promoter, P97, in vivo and in vitro from a negative element overlapping the transcription-initiation site.  The Journal of general virology.  2009 October. 90(Pt 10):2402-12.
[PubMed]

Lace M, Anson J, Klingelhutz A, Harada H, Taniguchi T, Bossler A, Haugen T, Turek L.  Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1.  Carcinogenesis.  2009 August. 30(8):1336-44.
[PubMed]

Lace M, Isacson C, Anson J, Lörincz A, Wilczynski S, Haugen T, Turek L.  Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture.  Journal of virology.  2009 August. 83(15):7457-66.
[PubMed]

Haugen T, Lace M, Ishiji T, Sameshima A, Anson J, Turek L.  Cellular factors are required to activate bovine papillomavirus-1 early gene transcription and to establish viral plasmid persistence but are not required for cellular transformation.  Virology.  2009 June. 389(2-Jan):82-90.
[PubMed]

Lace M, Anson J, Turek L, Haugen T.  Functional mapping of the human papillomavirus type 16 E1 cistron.  Journal of virology.  2008 November. 82(21):10724-34.
[PubMed]

Lace M, Anson J, Thomas G, Turek L, Haugen T.  The E8--E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes.  Journal of virology.  2008 November. 82(21):10841-53.
[PubMed]

Smith E, Rubenstein L, Ritchie J, Lee J, Haugen T, Hamsikova E, Turek L.  Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers?.  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.  2008 August. 17(8):2087-96.
[PubMed]

Smith E, Wang D, Rubenstein L, Morris W, Turek L, Haugen T.  Association between p53 and human papillomavirus in head and neck cancer survival.  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.  2008 February. 17(2):421-7.
[PubMed]

Smith E, Wang D, Kim Y, Rubenstein L, Lee J, Haugen T, Turek L.  P16INK4a expression, human papillomavirus, and survival in head and neck cancer.  Oral oncology.  2008 February. 44(2):133-42.
[PubMed]

Smith E, Swarnavel S, Ritchie J, Wang D, Haugen T, Turek L.  Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents.  The Pediatric infectious disease journal.  2007 September. 26(9):836-40.
[PubMed]

Pyeon D, Newton M, Lambert P, den Boon J, Sengupta S, Marsit C, Woodworth C, Connor J, Haugen T, Smith E, Kelsey K, Turek L, Ahlquist P.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.  Cancer research.  2007 May. 67(10):4605-19.
[PubMed]

Smith E, Ritchie J, Pawlita M, Rubenstein L, Haugen T, Turek L, Hamsikova E.  Human papillomavirus seropositivity and risks of head and neck cancer.  International journal of cancer. Journal international du cancer.  2007 February. 120(4):825-32.
[PubMed]

Parker T, Smith E, Ritchie J, Haugen T, Vonka V, Turek L, Hamsikova E.  Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors.  Oral oncology.  2006 March. 42(3):288-96.
[PubMed]

Berger K, Barriga F, Lace M, Turek L, Zamba G, Domann F, Lee J, Klingelhutz A.  Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.  Virology.  2006. 356(2-Jan):68-78.
[PubMed]

Tachezy R, Klozar J, Saláková M, Smith E, Turek L, Betka J, Kodet R, Hamsíková E.  HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic.  Oral diseases.  2005 May. 11(3):181-5.
[PubMed]

Wang D, Ritchie J, Smith E, Zhang Z, Turek L, Haugen T.  Alcohol dehydrogenase 3 and risk of squamous cell carcinomas of the head and neck.  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.  2005 March. 14(3):626-32.
[PubMed]

Smith E, Johnson S, Ritchie J, Feddersen D, Wang D, Turek L, Haugen T.  Persistent HPV infection in postmenopausal age women.  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.  2004 November. 87(2):131-7.
[PubMed]

Smith E, Ritchie J, Yankowitz J, Wang D, Turek L, Haugen T.  HPV prevalence and concordance in the cervix and oral cavity of pregnant women.  Infectious diseases in obstetrics and gynecology.  2004 June. 12(2):45-56.
[PubMed]

Klussmann J, Dinh S, Guntinas-Lichius O, Wittekindt C, Weissenborn S, Wieland U, Dienes H, Hoffmann T, Smith E, Turek L, Speel E, Pfister H.  HPV-associated tonsillar cancer - An update.  HNO.  2004 March. 52(3):208-18.
[PubMed]

Smith E, Ritchie J, Summersgill K, Hoffman H, Wang D, Haugen T, Turek L.  Human papillomavirus in oral exfoliated cells and risk of head and neck cancer.  Journal of the National Cancer Institute.  2004 March. 96(6):449-55.
[PubMed]

Smith E, Ritchie J, Summersgill K, Klussmann J, Lee J, Wang D, Haugen T, Turek L.  Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers.  International journal of cancer. Journal international du cancer.  2004 February. 108(5):766-72.
[PubMed]

Smith E, Ritchie J, Yankowitz J, Swarnavel S, Wang D, Haugen T, Turek L.  Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission.  Sexually transmitted diseases.  2004 January. 31(1):57-62.
[PubMed]

Ritchie J, Smith E, Summersgill K, Hoffman H, Wang D, Klussmann J, Turek L, Haugen T.  Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx.  International journal of cancer. Journal international du cancer.  2003 April. 104(3):336-44.
[PubMed]

Smith E, Ritchie J, Levy B, Zhang W, Wang D, Haugen T, Turek L.  Prevalence and persistence of human papillomavirus in postmenopausal age women.  Cancer detection and prevention.  2003. 27(6):472-80.
[PubMed]

Sprague D, Phillips S, Mitchell C, Berger K, Lace M, Turek L, Klingelhutz A.  Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes.  Virology.  2002 September. 301(2):247-54.
[PubMed]

Smith E, Levy B, Ritchie J, Jia J, Wang D, Haugen T, Turek L.  Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers?.  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP).  2002 June. 11(3):295-305.
[PubMed]

Summersgill K, Smith E, Levy B, Allen J, Haugen T, Turek L.  Human papillomavirus in the oral cavities of children and adolescents.  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.  2001 January. 91(1):62-9.
[PubMed]

Smith E, Summersgill K, Allen J, Hoffman H, McCulloch T, Turek L, Haugen T.  Human papillomavirus and risk of laryngeal cancer.  The Annals of otology, rhinology, and laryngology.  2000 November. 109(11):1069-76.
[PubMed]

Kutza J, Smith E, Levy B, Jian J, Haugen T, Turek L.  Use of hormone replacement therapy (Hrt) And detection of human papillomavirus (Hpv) Dna in postmenopausal women.  Annals of epidemiology.  2000 October. 10(7):465-466.
[PubMed]

Summersgill K, Smith E, Kirchner H, Haugen T, Turek L.  p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer.  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.  2000 September. 90(3):334-9.
[PubMed]

Smith E, Hoffman H, Summersgill K, Kirchner H, Turek L, Haugen T.  Human papillomavirus and risk of oral cancer.  The Laryngoscope.  1998 July. 108(7):1098-103.
[PubMed]

Sethi S, Müller M, Schneider A, Blettner M, Smith E, Turek L, Wahrendorf J, Gissmann L, Chang-Claude J.  Serologic response to the E4, E6, and E7 proteins of human papillomavirus type 16 in pregnant women.  American journal of obstetrics and gynecology.  1998 February. 178(2):360-4.
[PubMed]

Smith E, Johnson S, Figuerres E, Mendoza M, Fedderson D, Haugen T, Turek L.  The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy.  Gynecologic oncology.  1997 June. 65(3):441-6.
[PubMed]

Bostik P, Turek L, Haugen T.  Simple method for selective amplification of cDNA from a defined promoter.  BioTechniques.  1997 February. 22(2):300-2, 304, 306.
[PubMed]

Turek L, Smith E.  The genetic program of genital human papillomaviruses in infection and cancer.  Obstetrics and gynecology clinics of North America.  1996 December. 23(4):735-58.
[PubMed]

Chang-Claude J, Schneider A, Smith E, Blettner M, Wahrendorf J, Turek L.  Longitudinal study of the effects of pregnancy and other factors on detection of HPV.  Gynecologic oncology.  1996 March. 60(3):355-62.
[PubMed]

Smith E, Johnson S, Cripe T, Perlman S, McGuinness G, Jiang D, Cripe L, Turek L.  Perinatal transmission and maternal risks of human papillomavirus infection.  Cancer detection and prevention.  1995. 19(2):196-205.
[PubMed]

Ushikai M, Lace M, Yamakawa Y, Kono M, Anson J, Ishiji T, Parkkinen S, Wicker N, Valentine M, Davidson I, Turek L.  trans activation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: cooperation with activation domains of cellular transcription factors.  Journal of virology.  1994 October. 68(10):6655-66.
[PubMed]

Turek L.  The structure, function, and regulation of papillomaviral genes in infection and cervical cancer.  Advances in virus research.  1994. 44:305-56.
[PubMed]

Smith E, Pignatari S, Gray S, Haugen T, Turek L.  Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction.  Archives of otolaryngology--head & neck surgery.  1993 May. 119(5):554-7.
[PubMed]

Ishiji T, Lace M, Parkkinen S, Anderson R, Haugen T, Cripe T, Xiao J, Davidson I, Chambon P, Turek L.  Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells.  The EMBO journal.  1992 June. 11(6):2271-81.
[PubMed]

Pignatari S, Smith E, Gray S, Shive C, Turek L.  Detection of human papillomavirus infection in diseased and nondiseased sites of the respiratory tract in recurrent respiratory papillomatosis patients by DNA hybridization.  The Annals of otology, rhinology, and laryngology.  1992 May. 101(5):408-12.
[PubMed]

Smith E, Johnson S, Cripe T, Pignatari S, Turek L.  Perinatal vertical transmission of human papillomavirus and subsequent development of respiratory tract papillomatosis.  Annals of otology, rhinology and laryngology.  1991 June. 100(6):479-83.
[PubMed]

Smith E, Johnson S, Jiang D, Zaleski S, Lynch C, Brundage S, Anderson R, Turek L.  The association between pregnancy and human papilloma virus prevalence.  Cancer detection and prevention.  1991. 15(5):397-402.
[PubMed]

Berberich S, Macias M, Zhang L, Turek L, Stoltzfus C.  Comparison of Rous sarcoma virus RNA processing in chicken and mouse fibroblasts: evidence for double-spliced RNA in nonpermissive mouse cells.  Journal of virology.  1990 September. 64(9):4313-20.
[PubMed]

Cripe T, Alderborn A, Anderson R, Parkkinen S, Bergman P, Haugen T, Pettersson U, Turek L.  Transcriptional activation of the human papillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-1-responsive modules.  The New biologist.  1990 May. 2(5):450-63.
[PubMed]

Levenson R, Brinckmann U, O'Banion M, Androphy E, Schiller J, Tabatabai F, Turek L, Neary K, Chin M, Broker T.  Papillomavirus-associated inductions of cellular proteins in mouse C127 cells: correlation with the presence of open reading frame E2.  Virology.  1989 September. 172(1):170-9.
[PubMed]

Kleinheinz A, von Knebel Doeberitz M, Cripe T, Turek L, Gissmann L.  Human papillomavirus early gene products and maintenance of the transformed state of cervical cancer cells in vitro.  Current topics in microbiology and immunology.  1989. 144:175-9.
[PubMed]

Haugen T, Turek L, Mercurio F, Cripe T, Olson B, Anderson R, Seidl D, Karin M, Schiller J.  Sequence-specific and general transcriptional activation by the bovine papillomavirus-1 E2 trans-activator require an N-terminal amphipathic helix-containing E2 domain.  The EMBO journal.  1988 December. 7(13):4245-53.
[PubMed]

Cripe T, Haugen T, Turk J, Tabatabai F, Schmid P, Dürst M, Gissmann L, Roman A, Turek L.  Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis.  The EMBO journal.  1987 December. 6(12):3745-53.
[PubMed]

Stoltzfus C, Chang L, Cripe T, Turek L.  Efficient transformation by Prague A Rous sarcoma virus plasmid DNA requires the presence of cis-acting regions within the gag gene.  Journal of virology.  1987 November. 61(11):3401-9.
[PubMed]

Haugen T, Cripe T, Ginder G, Karin M, Turek L.  Trans-activation of an upstream early gene promoter of bovine papilloma virus-1 by a product of the viral E2 gene.  The EMBO journal.  1987 January. 6(1):145-52.
[PubMed]

Turek L, Byrne J, Lowy D, Dvoretzky I, Friedman R, Howley P.  Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells.  Proceedings of the National Academcy of Sciences of the United State of America.  1982 December. 79(24):7914-8.
[PubMed]

Turek L, Oppermann P.  Spontaneous conversion of nontransformed avian sarcoma virus-infected rat cells to the transformed phenotype.  Journal of virology.  1980 August. 35(2):466-78.
[PubMed]

Ruscetti S, Turek L, Sherr C.  Three independent isolates of feline sarcoma virus code for three distinct gag-x polyproteins.  Journal of virology.  1980 July. 35(1):259-64.
[PubMed]

Donner L, Turek L, Ruscetti S, Fedele L, Sherr C.  Transformation-defective mutants of feline sarcoma virus which express a product of the viral src gene.  Journal of virology.  1980 July. 35(1):129-40.
[PubMed]

Sherr C, Fedele L, Donner L, Turek L.  Restriction endonuclease mapping of unintegrated proviral DNA of Snyder-Theilen feline sarcoma virus: localization of sarcoma-specific sequences.  Journal of virology.  1979 December. 32(3):860-75.
[PubMed]

Donner L, Turek L.  Chilling of somatic cells unnecessary for Sendai virus-induced heterokaryon formation.  Somatic cell genetics.  1976 January. 2(1):77-80.
[PubMed]

Donner L, Sainerová H, Svoboda J, Turek L.  Treatment of RSV-transformed "poorly" virogenic and non-virogenic mammalian cell lines with inhibitors of protein synthesis: failure to potentiate RSV rescue.  Folia biologica.  1975. 21(4):283-6.
[PubMed]

Donner L, Turek L, Svoboda J.  Absence of RSV production in enucleated RSV-transformed virogenic Mammalian cells fused with chick embryo fibroblasts.  International journal of cancer. Journal international du cancer.  1974 November. 14(5):657-61.
[PubMed]

Date Last Modified: 07/31/2013 - 10:51:40